A Randomized, Double Blind Trial of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-016)
A Randomized, Double Blind Trial of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-016)
Trial Category:
Breast
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
